atalent Pharma Solutions has today announced that work has commenced to expand its highly potent and cytotoxic clinical drug packaging capabilities within its 450,000 sq. ft. Kansas City, MO campus.
Somerset, N.J. – November 3, 2014 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has today announced that work has commenced to expand its highly potent and cytotoxic clinical drug packaging capabilities within its 450,000 sq. ft. Kansas City, MO campus.
The expansion will increase the available packaging space for highly potent compounds adding two large packaging suites, a sampling lab, and space for various storage conditions. Segregated and separated from non-potent manufacturing operations, the new 6,000 sq. ft. facility is capable of handling SafeBridge® Category 3, 4 and cytotoxic compounds. Completion is expected in January 2015.
Catalent already has several highly potent and cytotoxic drug packaging suites in its clinical supply facility in Bolton, UK, providing end-to-end clinical supply solutions from clinical supply management, comparator sourcing and primary packaging to storage and distribution globally.
“Customer demand for specialty clinical packaging has grown as the proportion of highly potent molecules in drug development pipelines increases,” commented Gerry Hepburn, Chief Operating Officer, Vice President and General Manager of Catalent’s Clinical Supply Services business. “Industry-wide clinical packaging capabilities are insufficient to support future demand and this expansion will provide our customers with the necessary capacity and expertise to develop and commercialize potent and cytotoxic compounds.”
Catalent’s Kansas City campus provides a range of fully integrated support services, from formulation development and small and large molecule analytical testing, to clinical and commercial scale manufacturing and packaging of a variety of oral solid dose forms. Its co-located end-to-end drug development solutions provide speed and flexibility to help Catalent’s customers accelerate their drug development programs to market.
*SafeBridge is a registered trademark of SafeBridge Consultants, Inc.
+44 (0)7580 041073
+44 (0) 161 728 5880
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™
This press release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”, “likely”, “may”, “will”, “would” or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent, Inc.’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in its Form 10-K release for the fiscal year ended June 30, 2014 filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent, Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments unless required by law.